simvastatin + metformin

Simvastatin + metformin is a combination therapy investigated for the treatment of polycystic ovary syndrome (PCOS). Simvastatin is an HMG-CoA reductase inhibitor (statin) typically used for dyslipidemia, while metformin is a biguanide antihyperglycemic agent. In the context of PCOS, this combination aims to address both the metabolic and endocrine dysfunctions associated with the disorder, such as hyperandrogenism, insulin resistance, and systemic inflammation. A clinical trial conducted by the Poznan University of Medical Sciences (NCT00396513) evaluated this combination's efficacy in improving menstrual cyclicity, reducing testosterone levels, and enhancing lipid profiles and endothelial function in women with PCOS. The study compared the combination against monotherapy with either agent, finding that simvastatin was particularly effective in improving lipid profiles while both drugs contributed to androgen reduction.

Other names

simvastatin and metformin combinationmetformin and simvastatin combination